DIGITAL NANOGENETICS, LLC

Biotech

Exo-Seq, a single-molecule DNA sequencing instrument and consumable chip using exonuclease digestion and nanochannel electrophoresis to identify individual nucleotides.

Grants
$343K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Exo-Seq for the single molecule of DNA molecules$342,831
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2845Solid Biosciences—$109M
2846Lomond Therapeutics——
2847Cardurion Pharmaceuticals—$350M
2848DIGITAL NANOGENETICS, LLC——
2849RETINAL SOLUTIONS LLC——
2850Stipple Bio—$87M
2851PPI PHARMACEUTICALS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.